Kent Meningitis Outbreak Reaches 27 Cases as Vaccine Eligibility Broadened Across Region
Seven new meningitis B cases confirmed in Kent push the outbreak total to 27, prompting the government to widen vaccination access across universities, schools, and nightclub visitors.
Kent Meningitis Crisis Deepens as Government Widens Vaccination Drive
The UK government has significantly broadened its meningitis vaccination programme across Kent following the confirmation of seven additional cases, bringing the total number of reported infections in the region to 27. Health Secretary Wes Streeting visited the University of Kent to announce the expanded response and urged anyone who attended Club Chemistry nightclub in Canterbury between 5 March and 15 March to seek both antibiotics and vaccination without delay.
Who Is Now Eligible for the Vaccine?
The expanded eligibility covers everyone who was previously offered preventive antibiotics — a group that includes students at the University of Kent and Canterbury Christ Church University, as well as sixth formers attending the four schools and colleges where confirmed or suspected meningitis cases have been recorded. The University of Kent confirmed that all of its students and staff are now eligible to receive the vaccine.
Professor Susan Hopkins, Chief Executive of the UK Health Security Agency (UKHSA), reinforced the message clearly: "By extending the vaccination programme to everyone who has been offered preventive antibiotics, we are taking an important additional step to protect those most likely to have been exposed. The message is simple: if you have had the antibiotic, you are also eligible for the vaccination."
The UKHSA also noted that additional individuals may be offered both the vaccine and preventive antibiotics on a case-by-case basis.
Understanding the Scale of the Outbreak
As of Thursday, 15 laboratory cases have been officially confirmed, while 12 further notifications remain under investigation. The outbreak has already claimed two lives — one school pupil and one university student — and authorities have described it as the fastest-growing outbreak they have ever encountered.
Officials believe the current strategy of combining targeted vaccination with preventive antibiotics is showing signs of effectiveness. The bacteria responsible has been identified as a known strain of meningitis B. However, the reasons behind the unusually high number of cases stemming from a single source remain unclear.
Professor Robin May, Chief Scientific Officer at the UKHSA, told BBC Breakfast that two possible explanations are being examined: "One is that there might be something about the kind of behaviours that individual people are doing. The other possibility is the bacteria itself may have evolved to be better at transmitting."
Vaccine Queues Overwhelmed as Demand Surges
Demand for the meningitis B vaccine has been overwhelming. So far, 600 doses have been administered at the University of Kent's Canterbury campus, and more than 6,500 precautionary antibiotic doses have been distributed to students. Despite this, more than 100 people were turned away on Thursday after the university was forced to close its vaccine queue due to capacity constraints, needing to wrap up the clinic by 5pm. The queue was set to reopen on Friday morning.
New Vaccination Centres Opening Across Kent
To meet growing demand, several new vaccination sites are opening across the county. From Friday:
- Faversham Health Centre – Opens at 9am Friday, also operating through Saturday
- Vicarage Lane Clinic, Ashford – Opening Friday
- University of Kent, Canterbury – Resuming Friday morning
London Case Linked to Kent Outbreak
The UKHSA confirmed that a student at a higher education institution in London has also been diagnosed with meningitis, with their case directly linked to the Kent outbreak. While the agency has issued a broader NHS alert across England raising awareness of meningitis signs and symptoms, officials were careful to stress this does not indicate the outbreak is on course to spread nationally.
Private Vaccine Access Being Eased
With pharmacies reporting difficulty sourcing vaccines for privately paying customers, the UKHSA announced the release of 20,000 doses from NHS supply to support private provision. This move is expected to enable up to 2,000 pharmacies to receive stock within 48 hours.
However, concerns remain about affordability. Dr Simon Williams, a public health researcher at Swansea University, welcomed the expanded access but cautioned that private vaccines carry a significant cost burden. "They are expensive privately and many may not be able to afford them, including students who may not have much disposable income," he said. He also raised the broader question of whether the government should consider making vaccines more widely available to university and sixth form students pending a review by the Joint Committee on Vaccination and Immunisation (JCVI).
Olivier Picard, Chair of the National Pharmacy Association, welcomed the additional supply but warned it was unlikely to be sufficient, with pharmacies receiving requests from "hundreds of thousands of patients seeking vaccination."
Recognising the Symptoms
Health authorities are urging the public to remain alert to the signs of invasive meningococcal disease, particularly given that the MenB vaccine does not protect against all strains of meningitis nor prevent bacterial transmission within communities.
Trish Mannes, UKHSA Regional Deputy Director for South-East England, stressed: "It is therefore still hugely important that people are aware of the signs and symptoms of invasive meningococcal disease, and that they seek immediate medical attention if they or anyone they know develops these signs and symptoms."
